Acumen
Charlottesville, Virginia, United States · Biotechnology · 200 employees
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease. The company's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology.
Funding history
- Funding Round — $50.0M — Nov 2023
Recent signals
- Jan 05, 2025: $6.0 million Deal Goes to Acumen Llc
- Nov 06, 2024: Acumen Pharmaceuticals Appoints Amy Schacterle, Ph.D. as Chief Regulatory Officer & Head of Quality and Expresses Gratitude to Retiring Vice President of Regulatory Affairs Janice Hitchcock, Ph.D.
- Jul 25, 2024: Acumen Llc Secures Contract Worth 4413537.0 USD
- Feb 01, 2024: Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
- Nov 13, 2023: Raised $50.0M
See plans & pricing → Track Acumen’s funding, hiring, and signals — with verified contacts — on Fundz.